Navigation Links
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Date:10/8/2008

fluenza vaccine generated broader, more balanced antibody responses than unformulated vaccine, and also generated influenza-specific T-cell responses. Adjusting the ratio of Vaxfectin(R) to vaccine drove substantial increases in either antibody or T-cell responses, without reducing the other type of response, compared with unformulated vaccine. The ability to favor primarily antibody or T-cell responses could provide important advantages in developing vaccines for specific applications.

H5N1 Pandemic Influenza Vaccine Phase 1 Trial Update

Vical reported in July that the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines achieved potentially protective levels of antibody responses (H5 hemagglutination inhibition, or HI, titers of at least 40 and at least a four-fold increase from baseline) in at least 50% and up to 67% of evaluable subjects in the higher dose cohorts in a 100-subject Phase 1 trial.

Following injections at Days 0 and 21, responses peaked by Day 56, and more than 90% of the responders had sustained responses through the last measurement (Day 84) at the time of the preliminary analysis. Expanded data presented today shows that in the two cohorts receiving the highest H5 DNA dose (1 mg), 80% to 100% of the responders had sustained responses through Day 182. Similar results for a vaccine deployed during the early stages of a pandemic outbreak could provide substantial protection to the at-risk population and potentially alter the course of the pandemic.

These results support further development of Vaxfectin(R)-formulated DNA vaccines, and could position them as potential alternatives to conventional vaccines. DNA vaccines are fundamentally different from conventional vaccines because they do not contain any part of the virus itself, and may offer compelling advantages in response to a pandemic outbreak because of significantly reduced development and manufacturing times. Vical is currently seeking funding to
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
(Date:7/24/2014)... 2014 Amgen (NASDAQ: AMGN ) today ... on Tuesday, July 29, 2014, after the close of the ... conference call with the investment community at 2 p.m. PT. ... A. Bradway , chairman and chief executive officer, and other ... of the conference call will be simultaneously broadcast over the ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... , NEW YORK, Oct. 16 Reportlinker.com announces ... in its catalogue. , Reportlinker Adds ... http://www.reportlinker.com/p0155102/Reportlinker-Adds-Allergan-Inc-PharmaVitae-Profile.html , Introduction , This ... Allergan in the Rx pharmaceutical sector. The profile ...
... NEW YORK, Oct. 16 Reportlinker.com ... report is available in its catalogue. ... Middle Eastern Pharmaceutical Market Outlook To ... landscape, growth opportunities , ...
Cached Medicine Technology:Reportlinker Adds Allergan Inc.: PharmaVitae Profile 2Reportlinker Adds Allergan Inc.: PharmaVitae Profile 3Reportlinker Adds Allergan Inc.: PharmaVitae Profile 4Reportlinker Adds Allergan Inc.: PharmaVitae Profile 5Reportlinker Adds Allergan Inc.: PharmaVitae Profile 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 11
(Date:7/25/2014)... July 25, 2014 As the category creator ... Xoçai is to transform and improve individual lives ... Adam Paul Green a successful Austin, Texas based ... at the end of the July to promote the up ... September 2014. , Eric Worre has been a leader in ...
(Date:7/25/2014)... At World T.E.A.M. Sports’ Adventure Team ... developmentally-disabled teens and young adults discovered that outdoor sporting ... and hiking can be challenging. , The third-year event, ... Chesapeake and Ohio Canal National Historical Park , included ... able-bodied. Under slightly overcast skies and temperatures in the ...
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer and retailer, ... party dresses . According to the company’s marketing specialist, ... at discounted prices, up to 59% off. The special ... , Most of the casual party dresses provided ... are popular for special designs, delicate craftsmanship and affordable ...
(Date:7/24/2014)... (PRWEB) July 25, 2014 A few ... Championships but the incredible high jump by Inika McPherson ... this past June, the USATF National Championships hosted the ... Zensah® athlete, Inika McPherson, won US Nationals with the ... new World Record for the biggest height over head ...
(Date:7/24/2014)... tumors, exposure to dim light at night made the ... to data published in Cancer Research , a ... negative effects of dim light exposure on tamoxifen treatment ... the night. , "Resistance to tamoxifen is a growing ... Steven M. Hill, PhD, professor of structural and cellular ...
Breaking Medicine News(10 mins):Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2
... SAN FRANCISCO, March 27 /PRNewswire/-- CVCTA Education, the ... introduced a new education,program that helps physicians reduce ... (CTA). When properly performed, radiation doses during CTA,are ... amount that has been attributed,to creating a health ...
... The following statement was,issued today by the law firm of ... given that a class action lawsuit was filed in the,United ... all purchasers of securities of NeuroMetrix Inc. (Nasdaq: NURO ... 6,2007, inclusive (the "Class Period")., If you wish to ...
... the American Association for Dental Research, convening this week ... scientists will be part of the Distinguished Lecture Series. ... will feature a Distinguished Lecture designed to interest delegates ... the Stemmons Ballroom at the Hilton Anatole Hotel., ...
... keynote presentations, symposia, and workshops that will anchor the ... Research, convening April 2 at the Hilton Anatole Hotel. ... , Optimizing the Survival of Ceramic ... Scherrer (University of Geneva, Switzerland), 3:15 p.m., Grand Ballroom ...
... most believed,they were not pregnant at the time ... each case., HARRISBURG, Pa., March 27 ... cases reported to the,Pennsylvania Patient Safety Authority in ... not pregnant, according to analysis published in the,Authority,s ...
... GPRO ) announced today that the Company will ... of Molecular Diagnostics Roundtable,Conference" in New York on April ... is scheduled to be webcast live and may be ... Gen-Probe,s website,at http://www.gen-probe.com . The webcast will be ...
Cached Medicine News:Health News:CVCTA Education Announces New LOW DOSE Initiative for CT Angiograms 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 4Health News:Eminent scientists to lecture in Dallas 2Health News:Eminent scientists to lecture in Dallas 3Health News:Keynoters, symposia, workshops highlight dental research meeting 2Health News:Keynoters, symposia, workshops highlight dental research meeting 3Health News:Keynoters, symposia, workshops highlight dental research meeting 4Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 2Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 3Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 4Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: